Back to results
US 12,622,929 B2Granted
Genetically engineered hematopoietic stem cells and uses thereof
AssigneeSyzygyMed Inc.
InventorsJoseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
Life of this patent
Estimating the term…
Abstract
Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
Claims19
A method of treating a hematopoietic malignancy, the method comprising administering to a subject in need thereof:
- a plurality of genetically engineered hematopoietic cells (HCs) comprising:
- (i) a gene encoding CD33 that is genetically engineered to have reduced or eliminated expression of CD33, and
- (ii) a gene encoding CLL-1 that is genetically engineered to have reduced or eliminated expression of CLL-1,
- wherein the hematopoietic malignancy is characterized by cells expressing CD33 and/or CLL-1,
- wherein the method comprises administering and/or the subject has been administered a therapeutically effective amount of at least one agent comprising an anti-CD33 binding domain, at least one agent comprising an anti-CLL-1 binding domain, or a combination thereof.
2 more elements
Dependencies are inferred from the claim text.